Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134654 · ClinicalTrials.gov registry record · Phase 2
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT00134654: Completed Phase 2 study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
NCT00134654 is a Phase 2 study of Prostate Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 48 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00134654, a Phase 2 study of Prostate Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to see if Premarin is useful against androgen-independent prostate cancer and to help understand how drugs such as Premarin may work.
Conditions Studied
Interventions
- DRUG Premarin
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Insitute - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2003-03 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
What the finished NCT00134654 record still lists
NCT00134654 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Premarin is the first listed.
NCT00134654 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00134654 about?
NCT00134654 is a clinical study titled "Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer". The purpose of this study is to see if Premarin is useful against androgen-independent prostate cancer and to help understand how drugs such as Premarin may work.
What is the current status of trial NCT00134654?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2003-03. Estimated completion is 2011-06.
What conditions does trial NCT00134654 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00134654?
The interventions under investigation include: Premarin (DRUG).
Who is sponsoring clinical trial NCT00134654?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00134654 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00134654's enrollment target sits among peer trials
48 496th of 735 higher than 235 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia